The Food and Drug Administration (FDA) has appointed Mark Goldberger, MD, MPH, as the new Medical Director for Emerging and Pandemic Threat Preparedness in FDA's Center for Biologics Evaluation and Research (CBER).

In this new position, Dr. Goldberger will "plan, coordinate and implement activities related to the development and evaluation of products for emerging and pandemic threats."

Acting FDA Commissioner Andrew von Eschenbach, MD says, "Emerging infectious diseases present a constant challenge for public health agencies, and FDA is committing resources and leadership to combat this growing threat. The creation of this position and Dr Goldberger's appointment together represent an important step forward in that effort."

"Dr. Goldberger has been at the forefront of combating other emerging infectious diseases, and we are grateful he has agreed once more to help tackle another monumental challenge, preparing for pandemic influenza and other future threats."

Jesse L. Goodman, MD, MPH, Director of CBER adds, "Dr. Goldberger's expertise and dedication to our public health mission will help enhance our preparedness activities. His regulatory and public health experience with a wide range of infectious diseases and emerging threats, including influenza, SARS, pandemic influenza and West Nile Virus, will be a major asset in our strategic response."